PR.com: Business Directory, Press Releases, Jobs, Products, Services, Articles
 
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | PR.com News on Your Site
 

Press Releases

 
iHealthcareAnalyst, Inc.

Press Release


Receive press releases from iHealthcareAnalyst, Inc.: By Email RSS Feeds:

Global Fragment-Based Drug Discovery (FBDD) Market Analysis: Services, End Users, Growth Trends and Forecast to 2020, New Research by iHealthcareAnalyst, Inc.


Fragment-Based Drug Discovery Market by Service Type (FBDD and HTS Comparative Analysis, Fragment Screening, Biophysical Techniques, NMR Spectroscopy, DSF Assay, Fluorescence Polarization, Isothermal Titration Calorimetry, X-Ray Crystallography, SPR, Bilayer Interferometry, Mass Spectrometry, Capillary Electrophoresis, Biochemical Assays, Non-Biophysical Techniques, Fragment Optimization), End Users (Academic and Research Institutes, Biopharmaceuticals, CROs) 2016-2020.

Maryland Heights, MO, February 22, 2017 --(PR.com)-- The global fragment-based drug discovery market is estimated to reach USD 650 Million in 2020, growing at a CAGR of 10.6% from 2016 to 2020. Increasing adoption of fragment-based screening programs by most of the major pharmaceutical companies, increasing availability of more assay options in research departments of most pharmaceutical and biotechnology companies for high hit rates of fragment-based screens are the major drivers of the global fragment-based drug discovery market, and are likely continue this trend during the forecast period.

Browse Fragment-Based Drug Discovery Market by Service Type or Components (Comparative Analysis of FBDD and HTS, Fragment Screening, Biophysical Techniques, NMR Spectroscopy, DSF Assay, Fluorescence Polarization, Isothermal Titration Calorimetry, X-Ray Crystallography, SPR, Bilayer Interferometry, Mass Spectrometry, Capillary Electrophoresis, Biochemical Assays, Non-Biophysical Techniques, Fragment Optimization), and End Users (Academic and Research Institutes, Biopharmaceutical Companies, and CROs) 2016-2020 report at https://www.ihealthcareanalyst.com/report/fragment-based-drug-discovery-market/

Fragment-based lead discovery (FBLD) also known as fragment-based drug discovery (FBDD) is a method used for finding lead compounds as part of the drug discovery process. It is based on identifying small chemical fragments, which may bind only weakly to the biological target, and then growing them or combining them to produce a lead with a higher affinity.

The global fragment-based drug discovery market segmentation is based on service types or components (comparative analysis of FBDD and HTS, fragment screening, biophysical techniques, NMR spectroscopy, DSF assay, fluorescence polarization, isothermal titration calorimetry, X-ray crystallography, SPR, bilayer interferometry, mass spectrometry, capillary electrophoresis, biochemical assays, non-biophysical techniques, fragment optimization), and end users (academic and research institutes, biopharmaceutical companies, and CROs).

The global fragment-based drug discovery market report provides market size (Revenue USD Million 2013 to 2020), market share, market trends and forecasts growth trends (CAGR%, 2016 to 2020). The global fragment-based drug discovery market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global fragment-based drug discovery market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.

Major players operating in the global fragment-based drug discovery market and included in this report are Astex Pharmaceuticals, Alveus Pharmaceuticals, Beactica AB, Charles River Laboratories International, Inc., Crown Bioscience, Inc., Emerald BioStructures, Evotec A.G., Kinetic Discovery, Proteros Fragments, Structure Based Design, Sygnature Discovery, and Sprint Bioscience AB.

To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/fragment-based-drug-discovery-market/

About Us
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.

Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
Website: https://www.ihealthcareanalyst.com
Contact Information
iHealthcareAnalyst, Inc.
Ana Aitawa
(314) 500-7508
Contact
https://www.ihealthcareanalyst.com/

Click here to view the list of recent Press Releases from iHealthcareAnalyst, Inc.
Promote Your Business